April price cut hits Japanese growth
This article was originally published in Scrip
Executive Summary
Japan's total prescription market grew by a modest 2.4% in the three months to June 30th, rising to ¥2,046.8 billion ($18.85 billion) at reimbursement prices but constrained by the regular biennial April 1st general price cut. This saw reimbursement levels cut by an average of 5.2%, with one-off reductions of around 10% for fast-growing angiotensin II antagonists.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.